AKT1 and stomatitis: Among PI3K/AKT/mTOR inhibitors, both alpelisib (OR, 0.24; 95% CrI, 0.035–1.0) and burparlisib (OR, 0.27; 95% CrI, 0.052–0.96) tended to exhibit lower risk of all-grade stomatitis than everolimus (Supplementary Figure 8).